News & Events about Point Biopharma Global Inc.
Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidanceINDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the Company or POINT), a company accelerating the discovery, development, and global access to life-...
INDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that the closing conditions, including Hart-Scott-Rodino antitrust clearance...
Globe Newswire
3 months ago
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA submission for PNT2001 program in H1 2023 INDIANAPOLIS, Oct. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma ...
Globe Newswire
4 months ago
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the Company or POINT), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the pricing of its public offering of 13,900,000 shares of ...
Globe Newswire
4 months ago
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR) was achieved in 60% of the 10 participants with evaluable disease at baseline PNT2002 was well tolerated ...